Tumor-treating fields: time for demystification
نویسندگان
چکیده
منابع مشابه
Tumor treating fields: a new standard treatment for glioblastoma?
PURPOSE OF REVIEW Tumor treating fields (TTFields), an external therapeutic device with antimitotic properties, is a Food and Drug Administration approved treatment for recurrent glioblastoma (GBM) that has been reported to be efficacious in newly diagnosed GBM as well. RECENT FINDINGS Preclinical data show that TTFields is an antimitotic agent that additionally augments response to alkylator...
متن کاملRationale and Background on Tumor-Treating Fields for Glioblastoma.
BACKGROUND More than 150 years after the first description of glioma cells, patients with glioblastoma (GBM) continue to have a poor prognosis despite standard-of-care therapy. With the introduction of tumor-treating fields (TTFields) therapy for the treatment of recurrent GBM in 2011 and for newly diagnosed GBM in 2015, the opportunity to increase progression-free survival and overall survival...
متن کاملTSViz: Demystification of Deep Learning Models for Time-Series Analysis
This paper presents a novel framework for demystification of convolutional deep learning models for time series analysis. This is a step towards making informed/explainable decisions in the domain of time series, powered by deep learning. There have been numerous efforts to increase the interpretability of image-centric deep neural network models, where the learned features are more intuitive t...
متن کاملTumor-Treating Fields: Answering the Concern About Quality of Life.
Since the 2005 publication of the randomized European Organization for Research and Treatment of Cancer/National Cancer Institute ofCancer trial that established concurrent radiotherapy (RT) and temozolomide for upfront treatment of glioblastoma (GBM),1 little progress has been made. Thus, itwas remarkablewhen the interim results for the EF-14 trial were published, documenting a 4.9-month incre...
متن کاملThe Evolving Role of Tumor Treating Fields in Managing Glioblastoma
Glioblastoma (GBM) is a devastating brain tumor with poor prognosis despite advances in surgery, radiation, and chemotherapy. Survival of patients with glioblastoma remains poor, with only 1 in 4 patients alive at 2 years, and a 5-year survival rate of about 5%. Recurrence is nearly universal and, after recurrence, prognosis is poor with very short progression-free survival and overall survival...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2018
ISSN: 0923-7534
DOI: 10.1093/annonc/mdy220